ARQT vs INCY: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

INCY is the larger of the two ($23.55B market cap): the incumbent the market prices for continued execution (13.40x forward earnings, beta 0.78). ARQT is the smaller challenger ($3.37B), actually pricier on forward earnings (24.37x): more room to run, but more to prove. If you believe in growth, ARQT fits: analysts expect its revenue to rise 30% next year, against 4% for INCY. If you believe in paying less for profit, INCY fits: it trades at 13.4x forward earnings, against 24.37x for ARQT.

ARQT vs INCY: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricARQTINCYWhat it tells you
Market cap$3.37B$23.55BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E24.3713.40Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E121.2358.96Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.630.78Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range48% of range61% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book13.784.18How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: INCY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ARQT and INCY affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARQT and INCY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARQT and INCY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Arcutis Biotherapeutics (ARQT) do?

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Its business is built around ZORYVE, a topical formulation of roflumilast that inhibits phosphodiesterase type 4 (PDE4), an anti-inflammatory target long used in dermatology. ZORYVE is sold as a cream 0.3% for plaque psoriasis, a foam 0.3% for seborrheic dermatitis, and cream formulations (0.15% and 0.05%) for atopic dermatitis spanning adults down to young children. The pitch to dermatologists is a steroid-free, once-daily topical with a clean tolerability profile that can be used on sensitive and intertriginous skin, and the company markets it as the leading branded topical across those three inflammatory skin conditions combined.

Full ARQT guide

What does Incyte Corporation (INCY) do?

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Its flagship product is Jakafi (ruxolitinib), an oral JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, which still generates the largest share of company revenue (roughly $758 million in Q1 2026, up about 7%). Beyond Jakafi, Incyte sells the topical cream Opzelura (ruxolitinib) for atopic dermatitis and vitiligo, plus a widening hematology and oncology lineup including Monjuvi/Minjuvi, Niktimvo, and Zynyz, and it funds a broad clinical pipeline of oncology and immunology candidates. In September 2026 the FDA approved Atebrioz (zilurgisertib), an Incyte-discovered ALK2 inhibitor, for fibrodysplasia ossificans progressiva; Incyte licensed US commercialization to Mirum Pharmaceuticals. On 16 November 2026 the European Commission approved Povofortay (povorcitinib) as the first once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa, and a US decision in that indication is expected in early 2027.

Full INCY guide

ARQT vs INCY: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ARQT drivers: Multi-indication ZORYVE expansion; Revenue growth reaching profitability.
  • INCY drivers: Jakafi franchise still growing near-term; Non-Jakafi revenue diversification.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. For INCY, the dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise.

ARQT or INCY: which should you pick?

If the story you believe is ARQT's (Multi-indication ZORYVE expansion), ARQT is the more direct way to own it; if it is INCY's (Jakafi franchise still growing near-term), INCY is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARQT and INCY guides.

ARQT vs INCY: the full fundamentals

ARQT. As of November 2026, Arcutis trades at about 6.6 times TTM sales and roughly 121 times trailing earnings, a multiple that only makes sense against forward estimates (about 24 times), since earnings are just turning positive. Analysts expect 2026 EPS of about $0.33, down from $0.43 before the Q3 miss, rising to about $1.09 in 2027 on revenue near $703 million, so the valuation leans on ZORYVE's revenue trajectory and on spending growing more slowly than sales. The eight analysts Yahoo Finance tracks have a mean target near $40.

INCY. The Q3 2026 loss makes the trailing P/E of about 59x misleading; on forward estimates Incyte trades near 13x earnings and about 3.9x sales, a modest multiple that reflects investor caution about the 2028 Jakafi cliff. Consensus calls for 2026 EPS of about $3.42 and a rebound to about $8.62 in 2027 on revenue near $6.3 billion. The 24 covering analysts lean buy, with a mean target near $132 against a close of $115.56 on 20 November 2026; Mizuho raised its target to $148 that day.

Headline figures (approximate, November 2026): ARQT shows revenue (ttm) ~$509 million, revenue growth (q3 2026, year over year) ~45%, q3 2026 net income ~$8.8 million (EPS $0.06 vs $0.17 est.), 2026 revenue guidance $535 to $545 million (raised); INCY shows revenue (ttm) ~$6.0B, q3 2026 revenue ~$1.56B (up ~14% YoY), margins (operating / net) ~32% / ~7%, net income (ttm) ~$403M (EPS ~$1.96), after a ~$785M Q3 2026 net loss.

The bottom line: ARQT vs INCY

ARQT and INCY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ARQT and INCY exposure against your real portfolio. It is not an investment adviser.

Wondering how ARQT or INCY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Arcutis Biotherapeutics

Ask Walnut's AI anything about ARQT and see how it fits what you own.

FAQ

What is the difference between ARQT and INCY?

+

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ARQT or INCY the better stock?

+

Neither is universally better. INCY is the larger incumbent; ARQT is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ARQT or INCY?

+

On forward P/E (as of November 2026), ARQT trades at 24.37x and INCY at 13.40x, so INCY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ARQT and INCY?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ARQT vs INCY?

+

ARQT: The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a loss of about $11 million on seasonality and reinvestment before Q2 recovered, and Q3 net income of about $8.8 million fell short of estimates as spending grew faster than revenue, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows. Valuation now assumes that growth continues: the stock trades near 6.6 times sales and about 24 times forward earnings, and an insider sale of about $1.4 million was disclosed in November 2026, and the infant label still depends on an FDA decision expected by February 23, 2027. INCY: The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. Pipeline and launch execution carry real uncertainty, and clinical trials can fail at any stage; the FDA previously rejected the extended-release Jakafi formulation before the XR version reached patients, and its uptake so far (about 3% of patients converted) is early. Reported earnings swing sharply: the Q3 2026 net loss of about $785 million pulled trailing EPS down to about $1.96, and full-year 2026 EPS consensus of about $3.42 is less than half of 2025's level before an expected rebound toward $8.62 in 2027. Competition is intensifying from larger peers with deeper resources in both oncology (Bristol Myers Squibb, Novartis, AbbVie) and inflammation/dermatology (AbbVie's Rinvoq, Eli Lilly's Olumiant, Pfizer, Regeneron). Morningstar has downgraded Incyte's economic moat toward none, citing the looming patent loss. Insiders sold shares in November 2026, per SEC filings. If non-Jakafi revenue does not scale to the $3 billion to $4 billion goal by 2030, the company could face a revenue gap late this decade.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ARQT or INCY; figures are approximate and dated (as of November 2026). Verify current data before investing.